Pierre Kemula
Director of Finance/CFO en CUREVAC N.V. .
Fortuna: 247 386 $ al 29/02/2024
Perfil
El Sr. Pierre Kemula es Director Financiero de CureVac NV y Director Financiero de CureVac AG. Anteriormente, el Sr. Kemula fue Director Financiero de Pixium Vision SA y Vicepresidente de Tesorería, Mercados Financieros y Finanzas Corporativas de Ipsen SA. Se licenció en la London School of Economics & Political Science.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
CUREVAC N.V.
0.03% | 31/03/2023 | 72 335 ( 0.03% ) | 247 386 $ | 29/02/2024 |
Cargos activos de Pierre Kemula
Empresas | Cargo | Inicio |
---|---|---|
CUREVAC N.V. | Director of Finance/CFO | 01/11/2016 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Director of Finance/CFO | 01/01/2016 |
Antiguos cargos conocidos de Pierre Kemula.
Empresas | Cargo | Fin |
---|---|---|
PIXIUM VISION | Director of Finance/CFO | 16/02/2017 |
IPSEN | Public Communications Contact | 01/01/2014 |
Formación de Pierre Kemula.
London School of Economics & Political Science | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
IPSEN | Health Technology |
PIXIUM VISION | Health Technology |
CUREVAC N.V. | Health Technology |
Empresas privadas | 1 |
---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |